Key Metrics
CiteScore 

8.1
Eigenfactor 

0.001 - 0.005
Impact Factor 

5 - 10
SJR 

Q2Oncology

SNIP 

1.39
Recommended pre-submission checks
Powered by 

Topics Covered on Experimental Hematology and Oncology
Experimental Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2590 | USD 2990 | GBP 2290 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in Experimental Hematology and Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Experimental Hematology and Oncology
MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc.
- 24 Jun 2026
- Experimental hematology & oncology
Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.
- 21 Jun 2026
- Experimental hematology & oncology
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.
- 20 Jun 2026
- Experimental hematology & oncology
A multimodal single-cell framework for ecosystem-level profiling of circulating tumor and non-tumor cells.
- 19 Jun 2026
- Experimental hematology & oncology
Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.
- 19 Jun 2026
- Experimental hematology & oncology
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
- 19 Jun 2026
- Experimental hematology & oncology
MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc.
- 24 Jun 2026
- Experimental hematology & oncology
Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.
- 21 Jun 2026
- Experimental hematology & oncology
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.
- 20 Jun 2026
- Experimental hematology & oncology
A multimodal single-cell framework for ecosystem-level profiling of circulating tumor and non-tumor cells.
- 19 Jun 2026
- Experimental hematology & oncology
Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.
- 19 Jun 2026
- Experimental hematology & oncology
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
- 19 Jun 2026
- Experimental hematology & oncology